Diagnostic Test Could Help Doctors Refine Prostate Cancer Treatment
Researchers found higher Decipher scores predicted worse outcomes and helped identify which men were most likely to benefit from abiraterone.
- Researchers at University College London unveiled findings on Friday showing the Decipher genetic test effectively identifies high-risk prostate cancer patients who benefit most from the hormone therapy abiraterone.
- Doctors currently face a difficult balancing act, as abiraterone blocks testosterone but causes side effects like fatigue, and there is no reliable method to determine which patients require such aggressive treatment.
- Data from more than 30,000 men showed that each 0.1 increase in a patient's Decipher score corresponds to a 49 per cent higher risk of metastasis and 38 per cent higher mortality risk.
- "Abiraterone saves lives but we may currently be over-treating some patients," Dr. Sarah Howlett told the Daily Mail, noting the test helps identify which patients truly need the therapy.
- While these findings strengthen evidence for Decipher, researchers emphasize that further validation in other datasets is required before the test is used routinely to guide clinical decisions for men with prostate cancer.
15 Articles
15 Articles
In prostate cancer, the therapy depends on the individual risk. In order to assess this better, a certain test could be used.
British STAMPEDE study shows that a special analysis of tumor tissue can help doctors determine who benefits most from additional hormonal therapy and who can avoid unnecessary side effects. A significant advance in the treatment of prostate cancer could enable doctors to choose the most appropriate therapy for each patient, avoiding intensive treatments when their benefit is limited. New results from the British STAMPEDE clinical study show tha…
New test could flag which men need aggressive prostate cancer treatment and which don't - NEW YORK TIMES POST
NEWYou can now listen to Fox News articles! A new diagnostic test could improve the prostate cancer experience for millions of men. Researchers at University College London (UCL) analyzed a tissue-based molecular test called Decipher to determine which men with high-risk prostate cancer were most likely to benefit from stronger treatment — and which might [...]
New test could flag which men need aggressive prostate cancer treatment and which don't – Democratic Accent
A new diagnostic test could improve the prostate cancer experience for millions of men. Researchers at University College London (UCL) analyzed a tissue-based molecular test called Decipher to determine which men with high-risk prostate cancer were most likely to benefit from stronger treatment — and which might avoid unnecessary medication and side effects. The analysis focused on abiraterone, a hormone therapy that was shown in the STAMPEDE cl…
Coverage Details
Bias Distribution
- 37% of the sources lean Left, 36% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
